Trial Profile
Combined Targeted Therapies for Triple Negative Advanced Breast Cancer A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Erlotinib (Primary) ; Paclitaxel (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 06 Nov 2018 Status changed from active, no longer recruiting to completed.
- 02 May 2017 Planned primary completion date changed from 1 Apr 2017 to 2 Mar 2018.
- 06 Jan 2016 Status changed from recruiting to active, no longer recruiting.